ARCHIVES

FDA Advisory Committee To Consider NDAs On Novantrone, HD MTX

This article is from The Cancer Letter archive.

Vol. 13 No. 46 | November 27, 1987

Download PDF Visit The Full Archive

Related Articles

Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes

April 15, 1977

NCI Advises Five-Year Limit On Tamoxifen Use, in Letter To Doctors

December 8, 1995

Needed Enhancement Or Unfunded Mandate? New NCI Program To Merge CCOP, NCCCP

July 13, 2012

In Brief: No Decision Yet On How CALB Cuts Will Be Made; Wyngaarden Of Duke Will Be New Director of NIH

January 29, 1982

NCI To Place 20% Cap On Grant Renewal Increases.

May 25, 2001

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

April 24, 1998